<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03356665</url>
  </required_header>
  <id_info>
    <org_study_id>DiTECT-HAT-WP2</org_study_id>
    <nct_id>NCT03356665</nct_id>
  </id_info>
  <brief_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection</brief_title>
  <acronym>DiTECT-WP2</acronym>
  <official_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Public Health, Democratic Republic of the Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Guinea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Sante Publique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Recherche Biomédicale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CIRDES</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study determines the diagnostic performance and cost of rapid diagnostic tests (RDTs)
      performed on human African trypanosomiasis clinical suspects in peripheral health centres,
      whether or not followed by serological and/or molecular tests on dried blood spots done at
      regional reference centres
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the last decade, the prevalence of Trypanosoma brucei gambiense human African
      trypanosomiasis (HAT) has fallen and HAT has been targeted for elimination. At low disease
      prevalence, integration of case finding into routine activities of peripheral health centres
      becomes crucial. However, HAT case detection by the peripheral health system with limited
      resources requires adapted diagnostic tests and test algorithms.

      The objective of the DiTECT-HAT-WP2 study is to determine the diagnostic performance and cost
      of rapid diagnostic tests (RDTs) performed on clinical suspects in peripheral health centres,
      whether or not followed by serological and/or molecular tests on filter paper done at
      regional reference centres.

      The DiTECT-HAT-WP2 study will be conducted in centres for diagnosis and treatment and in
      sites for serological screening in Guinea, Côte d'Ivoire and DR Congo. In these centres and
      sites, clinical suspects will be tested with several commercially available RDTs for HAT.
      Clinical suspects with at least 1 RDT positive result, will 1° undergo parasitological
      examination and 2° blood collection on filter paper for reference analysis in trypanolysis,
      LAMP, ELISA and real-time PCR in the regional reference laboratory. If the reference
      laboratory tests and parasitological examinations are all negative, the suspect is informed
      and considered free of HAT. If at least 1 reference test is positive, parasitological
      examinations are repeated at least twice at three months interval, unless trypanosomes are
      detected. In order to assess the sensitivity, specificity, Positive Predictive Values and
      Negative Predictive Values of each assay in these multiple populations, the data from the
      multiple assays in the 3 countries will be used in a Bayesian formulation of the Hui-Walter
      latent class model, to estimate the assay performances in the absence of a gold standard. As
      we will collect full cost information for the different algorithms, we will, in addition to
      estimating the diagnostic effectiveness of the assay, be able to estimate the cost of each
      assay in each setting, and rank this jointly with assay performance.

      The results will enable us to propose cost-effective test algorithms to detect HAT, adapted
      to peripheral health centres. Algorithms with high positive predictive values might allow
      test-and-treat scenarios without the need for complicated parasitological confirmations, once
      safe oral easy to use drugs become available to treat HAT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Sequential assignement</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The reference laboratory, generating the results for 4 index tests, is masked for index test and reference test results obtained at the clinical trial site</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on HAT clinical suspects</measure>
    <time_frame>6 months</time_frame>
    <description>Index tests: 4 RDTs on fresh blood, and for RDT positives also immune trypanolysis on DBS, ELISA on DBS, LAMP on DBS, RT-PCR on DBS.
Reference standard: for RDT positives only: combined results of parasitological examination at inclusion and if one of tests on DBS positive, at 3 and 6 months. Subjects negative in all RDTs are considered HAT negative</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on HAT clinical suspects</measure>
    <time_frame>6 months</time_frame>
    <description>Index tests: 4 RDTs on fresh blood, and for RDT positives also immune trypanolysis on DBS, ELISA on DBS, LAMP on DBS, RT-PCR on DBS.
Reference standard: for RDT positives only: combined results of parasitological examination at inclusion and if one of tests on DBS positive, at 3 and 6 months. Subjects negative in all RDTs are considered HAT negative.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>African Trypanosomiases</condition>
  <condition>West African; Trypanosomiasis</condition>
  <condition>Sleeping Sickness; West African</condition>
  <condition>Trypanosoma Brucei Gambiense; Infection</condition>
  <arm_group>
    <arm_group_label>Clinical suspect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Rapid diagnostic test (RDT)</intervention_name>
    <description>The 4 rapid diagnostic tests (RDT) will be carried out on fresh blood from clinical suspects. Only those subjects that are positive in at least 1 RDT will 1) undergo tests on DBS (immune trypanolysis, ELISA and DNA detection); 2) undergo parasitological confirmation (reference standard) at inclusion.</description>
    <arm_group_label>Clinical suspect</arm_group_label>
    <other_name>rHAT Sero-Strip (Coris Bioconcept, Belgium)</other_name>
    <other_name>SD Bioline HAT 1.0 (Standard Diagnostics Korea)</other_name>
    <other_name>HAT Sero-K-Set (Coris Bioconcept, Belgium)</other_name>
    <other_name>SD Bioline HAT 2.0 (Standard Diagnostics Korea)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serological and molecular tests on DBS</intervention_name>
    <description>Serological and molecular reference tests on dried blood spots (DBS) are carried out on RDT positive clinical suspects, which also undergo parasitological examination at inclusion (reference standard). If at least one of the serological or molecular reference tests on dried blood spots is positive, parasitological examination is repeated 3 and 6 months after inclusion. The combined results of parasitological examinations (at inclusion and if applicable at 3 and 6 months) serve as reference standard</description>
    <arm_group_label>Clinical suspect</arm_group_label>
    <other_name>Immune trypanolysis: presence of antibodies</other_name>
    <other_name>ELISA: on native LiTat 1.3 + LiTat 1.5 VSG</other_name>
    <other_name>Loopamp T. brucei Detection Kit (Eiken)</other_name>
    <other_name>RT-PCR: Trypanozoon 18S, Tbg TgsGP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Visit of or residence in a HAT endemic area

          -  Clinical suspicion of HAT based on: Recurrent fever not responding to anti-malarial
             medication; or Headache for a long duration (&gt;14 days); or presence of swollen lymph
             nodes in the neck; or Important weight loss; or Weakness; or Important scratching; or
             Amenorrhea, abortion(s), or sterility; or Coma; or Psychiatric problems
             (aggressiveness, apathy, mental confusion, increasing unusual hilarity, ...); or Sleep
             disruption (nocturnal insomnia and excessive diurnal sleeping); or Motor abnormalities
             (convulsions, abnormal movements, shaking, walking difficulties); or Speech disorders.

        Exclusion Criteria:

          -  Previously treated for HAT (irrespective of time elapsed since treatment)

          -  No informed consent

          -  &lt; 4 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veerle Lejon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherche pour le Developpement</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veerle Lejon, PhD</last_name>
    <phone>+33467593950</phone>
    <email>veerle.lejon@ird.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Programme Nationale de Lutte contre la trypanosomiase humaine Africaine</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crispin Lumbala, MD</last_name>
      <phone>+243 (0) 990027220</phone>
      <email>crispinlumbala@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Pierre Richet, Institut National de Santé Publique</name>
      <address>
        <city>Bouaké</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dramane Kaba, PhD</last_name>
      <phone>+225 5524464</phone>
      <email>kaba_dramane@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Programme Nationale de Lutte contre la Trypanosomiase Humaine Africaine, Ministère de Santé, Division Prévention et Lutte contre la Maladie</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamadou Camara, PhD</last_name>
      <phone>+224 664837199</phone>
      <email>mamadycamarafr@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
    <country>Côte D'Ivoire</country>
    <country>Guinea</country>
  </location_countries>
  <reference>
    <citation>Bisser S, Lumbala C, Nguertoum E, Kande V, Flevaud L, Vatunga G, Boelaert M, Büscher P, Josenando T, Bessell PR, Biéler S, Ndung'u JM. Sensitivity and Specificity of a Prototype Rapid Diagnostic Test for the Detection of Trypanosoma brucei gambiense Infection: A Multi-centric Prospective Study. PLoS Negl Trop Dis. 2016 Apr 8;10(4):e0004608. doi: 10.1371/journal.pntd.0004608. eCollection 2016 Apr.</citation>
    <PMID>27058033</PMID>
  </reference>
  <reference>
    <citation>Büscher P, Deborggraeve S. How can molecular diagnostics contribute to the elimination of human African trypanosomiasis? Expert Rev Mol Diagn. 2015 May;15(5):607-15. doi: 10.1586/14737159.2015.1027195. Epub 2015 Mar 18. Review.</citation>
    <PMID>25786994</PMID>
  </reference>
  <reference>
    <citation>Büscher P, Mertens P, Leclipteux T, Gilleman Q, Jacquet D, Mumba-Ngoyi D, Pyana PP, Boelaert M, Lejon V. Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study. Lancet Glob Health. 2014 Jun;2(6):e359-63. doi: 10.1016/S2214-109X(14)70203-7. Epub 2014 May 9.</citation>
    <PMID>25103304</PMID>
  </reference>
  <reference>
    <citation>Camara O, Camara M, Lejon V, Ilboudo H, Sakande H, Léno M, Büscher P, Bucheton B, Jamonneau V. Immune trypanolysis test with blood spotted on filter paper for epidemiological surveillance of sleeping sickness. Trop Med Int Health. 2014 Jul;19(7):828-31. doi: 10.1111/tmi.12316. Epub 2014 Apr 18.</citation>
    <PMID>24750463</PMID>
  </reference>
  <reference>
    <citation>Hasker E, Lutumba P, Mumba D, Lejon V, Büscher P, Kande V, Muyembe JJ, Menten J, Robays J, Boelaert M. Diagnostic accuracy and feasibility of serological tests on filter paper samples for outbreak detection of T.b. gambiense human African trypanosomiasis. Am J Trop Med Hyg. 2010 Aug;83(2):374-9. doi: 10.4269/ajtmh.2010.09-0735.</citation>
    <PMID>20682885</PMID>
  </reference>
  <reference>
    <citation>Jamonneau V, Bucheton B, Kaboré J, Ilboudo H, Camara O, Courtin F, Solano P, Kaba D, Kambire R, Lingue K, Camara M, Baelmans R, Lejon V, Büscher P. Revisiting the immune trypanolysis test to optimise epidemiological surveillance and control of sleeping sickness in West Africa. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e917. doi: 10.1371/journal.pntd.0000917.</citation>
    <PMID>21200417</PMID>
  </reference>
  <reference>
    <citation>Jamonneau V, Camara O, Ilboudo H, Peylhard M, Koffi M, Sakande H, N'Dri L, Sanou D, Dama E, Camara M, Lejon V. Accuracy of individual rapid tests for serodiagnosis of gambiense sleeping sickness in West Africa. PLoS Negl Trop Dis. 2015 Feb 2;9(2):e0003480. doi: 10.1371/journal.pntd.0003480. eCollection 2015 Feb.</citation>
    <PMID>25642701</PMID>
  </reference>
  <reference>
    <citation>Mitashi P, Hasker E, Mbo F, Van Geertruyden JP, Kaswa M, Lumbala C, Boelaert M, Lutumba P. Integration of diagnosis and treatment of sleeping sickness in primary healthcare facilities in the Democratic Republic of the Congo. Trop Med Int Health. 2015 Jan;20(1):98-105. doi: 10.1111/tmi.12404. Epub 2014 Oct 20.</citation>
    <PMID>25329353</PMID>
  </reference>
  <reference>
    <citation>Mitashi P, Hasker E, Ngoyi DM, Pyana PP, Lejon V, Van der Veken W, Lutumba P, Büscher P, Boelaert M, Deborggraeve S. Diagnostic accuracy of loopamp Trypanosoma brucei detection kit for diagnosis of human African trypanosomiasis in clinical samples. PLoS Negl Trop Dis. 2013 Oct 17;7(10):e2504. doi: 10.1371/journal.pntd.0002504. eCollection 2013.</citation>
    <PMID>24147176</PMID>
  </reference>
  <reference>
    <citation>Mumba D, Bohorquez E, Messina J, Kande V, Taylor SM, Tshefu AK, Muwonga J, Kashamuka MM, Emch M, Tidwell R, Büscher P, Meshnick SR. Prevalence of human African trypanosomiasis in the Democratic Republic of the Congo. PLoS Negl Trop Dis. 2011 Aug;5(8):e1246. doi: 10.1371/journal.pntd.0001246. Epub 2011 Aug 2.</citation>
    <PMID>21829736</PMID>
  </reference>
  <reference>
    <citation>Njiru ZK. Loop-mediated isothermal amplification technology: towards point of care diagnostics. PLoS Negl Trop Dis. 2012;6(6):e1572. doi: 10.1371/journal.pntd.0001572. Epub 2012 Jun 26. Review.</citation>
    <PMID>22745836</PMID>
  </reference>
  <reference>
    <citation>Van Meirvenne N, Magnus E, Buscher P. Evaluation of variant specific trypanolysis tests for serodiagnosis of human infections with Trypanosoma brucei gambiense. Acta Trop. 1995 Dec;60(3):189-99.</citation>
    <PMID>8907397</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2017</study_first_posted>
  <last_update_submitted>November 24, 2017</last_update_submitted>
  <last_update_submitted_qc>November 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diagnosis</keyword>
  <keyword>sensitivity</keyword>
  <keyword>specificity</keyword>
  <keyword>rapid diagnostic test</keyword>
  <keyword>molecular biology</keyword>
  <keyword>LAMP</keyword>
  <keyword>RT-PCR</keyword>
  <keyword>serology</keyword>
  <keyword>ELISA</keyword>
  <keyword>immune trypanolysis</keyword>
  <keyword>clinical symptom</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trypanosomiasis</mesh_term>
    <mesh_term>Trypanosomiasis, African</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

